Literature DB >> 26110722

Severe drug-induced skin reactions: clinical features, diagnosis, etiology, and therapy.

Maren Paulmann, Maja Mockenhaupt.   

Abstract

Drugs can induce severe skin reactions that differ in clinical presentation, prognosis, and therapy. The spectrum of these reactions not only includes bullous reactions such as Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and generalized bullous fixed drug eruption (GBFDE) but also acute generalized exanthematous pustulosis (AGEP) and drug reaction with eosinophilia and systemic symptoms (DRESS). If AGEP or DRESS is suspected, the diagnosis should be confirmed by thorough clinical examination, a skin biopsy, and specific laboratory tests. Crucial for the patient's prognosis, the causative agent should be rapidly identified and discontinued. It is therefore important to know the most frequent triggers of severe drug reactions, some of which may induce various reaction patterns. Depending on the clinical diagnosis, symptomatic and adequate supportive therapy, as well as systemic immunomodulatory treatments are used. The prognosis in SJS/TEN is often poor and depends on the patient's age and underlying conditions as well as the extent of skin detachment. The prognosis of GBFDE is somewhat better, but recurrences may lead to more severe disease manifestations. In DRESS, protracted and recurrent courses have been described, whereas AGEP usually resolves without problems.
© 2015 Deutsche Dermatologische Gesellschaft (DDG). Published by John Wiley & Sons Ltd.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26110722     DOI: 10.1111/ddg.12747

Source DB:  PubMed          Journal:  J Dtsch Dermatol Ges        ISSN: 1610-0379            Impact factor:   5.584


  27 in total

Review 1.  [Onychomycosis: Practical treatment strategies].

Authors:  E G Hasche; M Podda
Journal:  Hautarzt       Date:  2018-09       Impact factor: 0.751

2.  Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis in Association with Commonly Prescribed Drugs in Outpatient Care Other than Anti-Epileptic Drugs and Antibiotics: A Population-Based Case-Control Study.

Authors:  Noel Frey; Michael Bodmer; Andreas Bircher; Susan S Jick; Christoph R Meier; Julia Spoendlin
Journal:  Drug Saf       Date:  2019-01       Impact factor: 5.606

Review 3.  Management of the cutaneous adverse effects of antimelanoma therapy.

Authors:  Rose Congwei Liu; Germana Consuegra; Pablo Fernández-Peñas
Journal:  Melanoma Manag       Date:  2017-11-22

Review 4.  [Triggers of exanthematous drug eruptions: Stop intake, treat through or desensitization?]

Authors:  M Absmaier; T Biedermann; K Brockow
Journal:  Hautarzt       Date:  2017-01       Impact factor: 0.751

Review 5.  [Severe cutaneous drug reactions in children].

Authors:  M Mockenhaupt
Journal:  Hautarzt       Date:  2017-10       Impact factor: 0.751

Review 6.  [Severe skin reactions due to new medications].

Authors:  M Mockenhaupt; M Paulmann
Journal:  Hautarzt       Date:  2018-04       Impact factor: 0.751

Review 7.  [Acute life-threatening drug reactions of the skin].

Authors:  M Mockenhaupt
Journal:  Hautarzt       Date:  2018-05       Impact factor: 0.751

Review 8.  Severe Cutaneous Adverse Drug Reactions: Presentation, Risk Factors, and Management.

Authors:  S Shahzad Mustafa; David Ostrov; Daniel Yerly
Journal:  Curr Allergy Asthma Rep       Date:  2018-03-24       Impact factor: 4.806

9.  Enzalutamide induced acute generalized exanthematous pustulosis.

Authors:  Chloé Alberto; Maria Polina Konstantinou; Catherine Martinage; Eline Casassa; Emilie Tournier; Haleh Bagheri; Vincent Sibaud; Loïc Mourey; Juliette Mazereeuw-Hautier; Nicolas Meyer; Carle Paul; Cristina Bulai Livideanu
Journal:  J Dermatol Case Rep       Date:  2016-11-13

10.  [Unintended rechallenge : Generalized bullous fixed drug eruption in two elderly women].

Authors:  M Paulmann; M Mockenhaupt
Journal:  Hautarzt       Date:  2017-01       Impact factor: 0.751

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.